Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Tateishi K, et al. Among authors: agatsuma t. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39656678
Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: A multicenter retrospective study.
Ozawa R, Sonehara K, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, Kato A, Matsuo A, Hirabayashi T, Araki T, Komatsu M, Tateishi K, Hanaoka M. Ozawa R, et al. Among authors: agatsuma t. Cancer Med. 2024 Aug;13(15):e70080. doi: 10.1002/cam4.70080. Cancer Med. 2024. PMID: 39096117 Free PMC article.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: agatsuma t. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates.
Sue M, Tsubaki T, Ishimoto Y, Hayashi S, Ishida S, Otsuka T, Isumi Y, Kawase Y, Yamaguchi J, Nakada T, Ishiguro J, Nakamura K, Kawaida R, Ohtsuka T, Wada T, Agatsuma T, Kawasaki N. Sue M, et al. Among authors: agatsuma t. PLoS One. 2024 Jun 6;19(6):e0304985. doi: 10.1371/journal.pone.0304985. eCollection 2024. PLoS One. 2024. PMID: 38843278 Free PMC article.
Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients with Advanced Non-Small Cell Lung Cancer Treated with a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study.
Hirabayashi T, Sonehara K, Ozawa R, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Hirabayashi T, et al. Among authors: agatsuma t. Oncology. 2024;102(10):819-827. doi: 10.1159/000536120. Epub 2024 Feb 6. Oncology. 2024. PMID: 38320539 Free article.
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T, Kanda S, Obara M, Agatsuma T, Kakizaki Y, Hama M, Yamamoto H, Takada M, Yamamoto M, Matsuo A, Kondo D, Komatsu M, Sonehara K, Tateishi K, Hanaoka M, Koizumi T. Araki T, et al. Among authors: agatsuma t. Respir Investig. 2024 Mar;62(2):262-268. doi: 10.1016/j.resinv.2024.01.002. Epub 2024 Jan 20. Respir Investig. 2024. PMID: 38245931 Free article.
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T. Suzuki H, et al. Among authors: agatsuma t. Mol Cancer Ther. 2024 Mar 4;23(3):257-271. doi: 10.1158/1535-7163.MCT-23-0287. Mol Cancer Ther. 2024. PMID: 38205802 Free PMC article.
Redescription, molecular characterisation and Wolbachia endosymbionts of Mansonella (Tupainema) dunni (Mullin & Orihel, 1972) (Spirurida: Onchocercidae) from the common treeshrew Tupaia glis Diard & Duvaucel (Mammalia: Scandentia) in Peninsular Malaysia.
Mat Udin AS, Uni S, Rodrigues J, Martin C, Junker K, Agatsuma T, Low VL, Saijuntha W, Omar H, Zainuri NA, Fukuda M, Matsubayashi M, Kimura D, Takaoka H, Ramli R. Mat Udin AS, et al. Among authors: agatsuma t. Curr Res Parasitol Vector Borne Dis. 2023 Nov 23;5:100154. doi: 10.1016/j.crpvbd.2023.100154. eCollection 2024. Curr Res Parasitol Vector Borne Dis. 2023. PMID: 38193019 Free PMC article.
242 results